International Clinical Trial: To verify the efficacy and safety of the monoclonal antibody HMI-115 targeting the prolactin receptor in improving hyperprolactinemia induced by antipsychotic drugs

Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122688) titled 'To verify the efficacy and safety of the monoclonal antibody HMI-115 targeting the prolactin receptor in improving hyperprolactinemia induced by antipsychotic drugs' on April 16.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Beijing An Ding Hospital, Capital Medical University

Condition: Antipsychotic drug-induced hyperprolactinemia

Intervention: Experimental group:Administer 240mg of HMI-115 by subcutaneous injection

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-04-16

Target Sample Size: Experimental group:40;Control group:20;

Countries o...